nesiritide + sildenafil

Nesiritide + sildenafil is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Nesiritide is a recombinant B-type natriuretic peptide that acts as an agonist at the particulate guanylate cyclase receptor on vascular smooth muscle and endothelial cells, leading to increased intracellular cyclic GMP and resulting in vasodilation, natriuresis, and diuresis. It is primarily used for the intravenous treatment of acutely decompensated congestive heart failure with dyspnea at rest or minimal activity[1][5]. Sildenafil is a selective phosphodiesterase-5 (PDE5) inhibitor that increases cyclic GMP by inhibiting its breakdown, leading to relaxation of vascular smooth muscle. It is indicated for erectile dysfunction and pulmonary arterial hypertension[2][3][4]. The combination may theoretically enhance vasodilatory effects via complementary mechanisms on cGMP pathways but also carries an increased risk for hypotension due to additive effects on blood pressure regulation.

Other names

BNP and PDE-Vlow-dose nesiritide + sildenafilrecombinant B-type natriuretic peptide + sildenafil